

Listing of the Claims:

This listing of Claims will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn) A method of treating a human suffering from a disorder associated with dyslipidemia, said method comprising administering to the subject an effective amount of a purified non-human animal ApoA-I protein.
2. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is hypercholesterolemia.
3. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is cardiovascular disease.
4. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is atherosclerosis.
5. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is restenosis.
6. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is HDL or ApoA-I deficiency.
7. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is hypertriglyceridemia.
8. (Withdrawn) A method of treating a subject suffering from an infection, said method comprising administering to the subject an effective amount of a purified non-human animal ApoA-I protein.
9. (Withdrawn) The method of Claim 8 wherein the infection is bacterial.
10. (Withdrawn) The method of Claim 9 wherein the infection is septic shock.
11. (Withdrawn) The method of Claim 8 wherein the infection is viral.
12. (Withdrawn) The method of Claim 11 wherein the virus is influenza.

13. (Withdrawn) The method of Claim 11 wherein the virus is human immunodeficiency virus.
14. (Withdrawn) The method of Claim 11 wherein the virus is cytomegalovirus.
15. (Withdrawn) The method of Claim 11 wherein the virus is herpes simplex virus.
16. (Currently amended) A pharmaceutical composition comprising a purified non-human animal ApoA-I protein Apolipoprotein A-I protein (ApoA-I protein) and a pharmaceutically acceptable carrier, excipient or diluent.
17. (Currently amended) A non-human animal ApoA-I protein-lipid complex comprising a purified non-human animal ApoA-I protein and a lipid wherein said complex activates LCAT (lecithin cholesterol acyl transferase) activity, promotes cholesterol efflux and is suitable for administration in humans.
18. (Currently amended) A pharmaceutical composition comprising a the non-human animal ApoA-I protein-lipid complex of Claim 17.
19. (Previously presented) The composition of Claim 18 wherein the lipid is sphingomyelin.
20. (Previously presented) The composition of Claim 19 which is in the form of a lyophilized powder.
21. (Previously presented) The composition of Claim 19 which is in the form of a solution.
22. (Withdrawn) The method of Claim 1 or 8 wherein said subject is a human.
23. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is bovine.
24. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from chickens.
25. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from turkeys.

26. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from pigs.
27. (Withdrawn) The method of Claim 1 or 8 wherein about 0.5 mg/kg to about 100 mg/kg of the purified non-human animal ApoA-I protein is administered to said subject.
28. (Withdrawn) The method of administering the composition of Claim 26 wherein the composition is administered orally.
29. (Withdrawn) The method of Claim 26 wherein the composition is administered intravenously.
30. (Withdrawn) The method of Claim 26 wherein the composition is administered by inhalation.
31. (Withdrawn) The method of Claim 26 wherein the composition is administered once daily.
32. (Withdrawn) The method of Claim 26 wherein the composition is administered twice daily.
33. (Withdrawn) The method of Claim 26 wherein the composition is administered three times daily.
34. (Withdrawn) The method of Claim 26 wherein the composition is administered four times daily.
35. (Withdrawn) The method of Claim 26 wherein the composition is administered about once weekly.
36. (Withdrawn) The method of Claim 26 wherein the composition is administered about once monthly.
37. (Withdrawn) The method of Claim 26 wherein the composition is administered about every six months.
38. (Withdrawn) The method of Claim 26 wherein the composition is administered about once weekly for one month.

39. (New) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 38% human lecithin-cholesterol acyltransferase (LCAT) activation activity.
40. (New) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 40% human LCAT activation activity.
41. (New) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 43% human LCAT activation activity.
42. (New) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 45% human LCAT activation activity.
43. (New) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 350 mg.
44. (New) The pharmaceutical composition of Claim 43 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 35 mg.
45. (New) The pharmaceutical composition of Claim 44 wherein the non-human animal ApoA-I protein is in the amount of about 7 to about 35 mg.
46. (New) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is bovine.
47. (New) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is chicken.
48. (New) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is turkey.
49. (New) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is porcine.
50. (New) The pharmaceutical composition of Claim 16 wherein said non-human animal ApoA-I protein having greater than about 60% homology with native human ApoA-I protein.

51. (New) The pharmaceutical composition of Claim 50 wherein said non-human animal ApoA-I protein having greater than about 70% homology with native human ApoA-I protein
52. (New) The pharmaceutical composition of Claim 51 wherein said non-human animal ApoA-I protein having greater than about 80% homology with native human ApoA-I protein.
53. (New) The pharmaceutical composition of Claim 52 wherein said non-human animal ApoA-I protein having greater than about 90% homology with native human ApoA-I protein.
54. (New) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 350 mg.
55. (New) The ApoA-I protein-lipid complex of Claim 54 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 35 mg.
56. (New) The ApoA-I protein-lipid complex of Claim 55 wherein the non-human animal ApoA-I protein is in the amount of about 7 to about 35 mg.
57. (New) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 38% human LCAT activation activity.
58. (New) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 40% human LCAT activation activity.
59. (New) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 43% human LCAT activation activity.
60. (New) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 45% human LCAT activation activity.
61. (New) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein having greater than about 60% homology with native human ApoA-I protein.

62. (New) The ApoA-I protein-lipid complex of Claim 61 wherein said non-human animal ApoA-I protein having greater than about 70% homology with native human ApoA-I protein

63. (New) The ApoA-I protein-lipid complex of Claim 62 wherein said non-human animal ApoA-I protein having greater than about 80% homology with native human ApoA-I protein.

64. (New) The ApoA-I protein-lipid complex of Claim 63 wherein said non-human animal ApoA-I protein having greater than about 90% homology with native human ApoA-I protein.

65. (New) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is bovine.

66. (New) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is chicken.

67. (New) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is turkey.

68. (New) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is porcine.